SEPN trades 33.9% below Wall Street's consensus target of $50.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SEPN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Septerna, Inc. (SEPN) has a Wall Street consensus price target of $50.00, based on estimates from 7 covering analysts. With the stock currently trading at $37.34, this represents a potential upside of +33.9%. The company has a market capitalization of $1.68B.
Analyst price targets range from a low of $35.00 to a high of $60.00, representing a 50% spread in expectations. The median target of $52.50 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SEPN trades at a trailing P/E of -33.9x. Analysts expect EPS to grow -103.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
KYMRKymera Therapeutics, Inc. | $8.8B | $108.12 | $123.50 | +14.2% | Buy | — | 26 |
RXRXRecursion Pharmaceuticals, Inc. | $1.6B | $3.52 | $5.50 | +56.3% | Hold | — | 10 |
VKTXViking Therapeutics, Inc. | $4.4B | $38.04 | $93.60 | +146.1% | Buy | — | 24 |
GPCRStructure Therapeutics Inc. | $2.9B | $49.71 | $111.60 | +124.5% | Buy | — | 14 |
ACLXArcellx, Inc. | $6.7B | $115.07 | $112.45 | -2.3% | Hold | — | 18 |
TPVGTriplePoint Venture Growth BDC Corp. | $191M | $4.70 | $8.95 | +90.4% | Hold | 5.0x | 12 |
ARWRArrowhead Pharmaceuticals, Inc. | $11.1B | $78.89 | $84.00 | +6.5% | Buy | — | 21 |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
CGEMCullinan Therapeutics, Inc. | $1.1B | $18.40 | $31.00 | +68.5% | Buy | — | 8 |
Quick answers to the most common questions about buying SEPN stock.
The consensus Wall Street price target for SEPN is $50, representing 33.9% upside from the current price of $37.34. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SEPN has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $50 implies 33.9% upside from current levels.
SEPN's current price is $37.34 with a consensus target of $50 (33.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $60 for SEPN, while the most conservative target is $35. The consensus of $50 represents the median expectation. These targets typically reflect 12-month expectations.
SEPN is moderately covered, with 7 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SEPN stock forecast based on 7 Wall Street analysts shows a consensus price target of $50, with estimates ranging from $35 (bear case) to $60 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SEPN, with a "Buy" consensus rating and $50 price target (33.9% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SEPN analyst price targets range from $35 to $60, a 50% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.